ALGS Q3 2023 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-21.1% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$19M-588.8% margin

Net Income

-$18M-557.0% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

-53.0%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$86M

Total Liabilities

$31M

Stockholders' Equity

$55M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-21.1%
Gross Profit	$3M	$4M	-21.1%
Operating Income	-$19M	-$19M	-0.6%
Net Income	-$18M	-$19M	+3.1%